RenovoRx 2025 net loss widens on higher operating expenses

RenovoRx

30/03/2026 21:25

Overview

US oncology device maker's 2025 revenue rose to $1.1 mln in first full commercial year

Net loss widened to $11.2 mln as operating expenses increased with commercial and R&D investments

Company ended 2025 with $7 mln cash

Outlook

Company expects to complete TIGeR-PaC trial enrollment by mid-2026, with final data in 2027

RenovoRx plans to drive commercial growth for RenovoCath in 2026 and beyond

Result Drivers

PHYSICIAN ADOPTION - Co said revenue growth in 2025 was driven by initial physician adoption and demand at active commercial cancer centers

COMMERCIAL INFRASTRUCTURE - Co attributed higher operating expenses to buildout of commercial infrastructure, including sales and marketing capabilities

Company press release: ID:nGNX2674pG

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Net Income
-$11.2 mln
FY Basic EPS
-$0.32
FY Operating Expenses
$13.3 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for RenovoRx Inc is $5.50, about 386.7% above its March 27 closing price of $1.13

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)